Carboplatin and gemcitabinc combination in metastatic triple-negative anthracycline-and taxane-pretreated breast cancer patients: A phase II study

Journal of Chemotherapy

Volumn 23, Issue 1, 2011, Pages 40-43

  Maisano, R ^a   Zavettieri, M ^a   Azzarello, D ^a   Raffaele, M ^a   Maisano, M ^a   Bottari, M ^b   Nardi, M ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Breast cancer; Carboplatin; Triple negative

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; BISPHOSPHONIC ACID DERIVATIVE; BRCA1 PROTEIN; CARBOPLATIN; GEMCITABINE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXANE; TAXOID;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; DRUG ACTIVITY; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; SKIN METASTASIS; SOFT TISSUE METASTASIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VISCERAL METASTASIS; VOMITING; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DISEASE COURSE; GENETICS; METABOLISM; MIDDLE AGED; WATCHFUL WAITING;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CARBOPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEUTROPENIA; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS; WATCHFUL WAITING;

EID: 80051731918     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.1.40     Document Type: Article

References (15)

1. Sorlie T. Tibshirani R. Parker J. I Iastie T. Marion JS. Nobel A et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003: 100:8418-8423.
2. Foulkes WD. Stefansson IM. Chappuis PO. Begin LR. Gottin JR. Wrong N et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95:1482-1485.
3. Turner N, Tutt A. Ashworth A. I Iallmarks of BRCAness' in sporadic cancers. Nat Rev Cancer 2004: 4:814-819.
4. Nasr FL. Chahine GY. Kattan JG, Forhat FS, Mokaddem WT, Tueni EA et al. Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. Clin Breast Cancer 2004;5:117-122.
5. Laessig D, Stemmler I LI, Vehling-Kaiser U, Fashing PA, Melchert F, Kolbl H, et al. Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology 2007: 73:407-414.
6. Nagourney RA. Flam M. Link J, I leger S. Blitzer J, Lyons W et al. Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer. Clin Breast Cancer 2008; 8: 432-435.
7. Chan D., Yeo WL., Tiemsim Cordero M., Wong CI., Chaab B., Soo R., et al. Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. Invest New Drug 2009 Aug 25 [Epub ahead of print].
8. Therasse P, Arbuck SG. Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000: 92:205-216.
9. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989: 10: 1-10.
10. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1959: 53: 457-481.
11. Frasci G., Cornelia P., Rinaldo M., Iodice G., Di Bonito M., D'Aiuto M., et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 2009: 20: 1185-119
12. Silver DP., Richardson AL., Eklund AC., Wang ZC., Szallasi Z., Li Q., et al. Efficacy of neoadjuvant cisplatin in Triple-Negative Breast Cancer. J Clin Oncol 2010: 28: 1145-1153.
13. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G et al. Platinum-based chemotherapyin triple-negative breast cancer. Ann Oncol 2008: 19: 1847-1852.
14. O'haughnessy J. Osborne C. Pippen J. Yoffe M, Patt D, Monaghan G et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARPÌ) inhibitor. in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple negative breast cancer (TNBC): Results of randomized phase II trial. J Clin Oncol 2009: 27: 18s (suppl; abstr 3).
15. Carey LA, Rugo I IS, Marcom PK, Irvin W, Ferraro M. Burrows E et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008: 2b: suppl; abstr 1009.